Alexium International Group Ltd (ASX: AJX) Share Price and News

Mr Moore is the Senior Partner of the investment firm, Colinton Capital Partners. Prior to establishing Colinton Capital Partners in 2017, Mr Moore was a Global Partner of The Carlyle Group having established their operation in Australia in 2005. In his time at The Carlyle Group, he oversaw the Firm's investments in and served on the Boards of Directors of Coates Hire, Healthscope and QUBE. External Appointments include Deputy Chair for AMA Group from November 2018 to February 2024 and Non-Executive Director of Palla Pharma Limited from July 2016 to December 2021. Mr Moore is also a Non-Executive Director for AMS Group, Inc. since July 2018, LPA Energy Group, Dimeo Cleaning Services since December 2018, Monoova since November 2024, Clear Dynamics since June 2022, Aires Rail since July 2025 and LPA since April 2025. He is member of the Risk Committee.

Dr Stenson has a career with the research, development, manufacture, and commercialisation of new materials in the fields of coatings, adhesives, nonwovens, and pharmaceuticals. Dr Stenson was President and CEO of StanChem Inc. from January 2018 to April 2024. StanChem Inc. is comprised of two companies - StanChem Polymers which is a manufacturer of water-based polymers for the coatings and adhesives industries, and Albi Protective Coatings which focuses on the sector of fire protective intumescent paints and high performance industrial coatings. Prior to joining StanChem in 2017, Dr Stenson worked as a global technology director at Axalta Coating Systems. Between 2011 and 2016, Dr Stenson was the executive vice president of technology and product development at Ahlstrom for nonwoven and paper products. Prior to joining Ahlstrom, Dr Stenson was the vice president of technology for industrial and packaging coatings at Valspar based in Minneapolis and Zurich, Switzerland from 1993 until 2011. Dr Stenson is also the chairman of TopChem Pharmaceuticals (Ireland) which is a manufacturer of pharmaceutical ingredients. External Appointments include Director for TopChem Pharmaceuticals (Ireland) Limited since January 2005 to April 2024; Director for Deltech (StanChem) Holdings, LLC from July 2017 to April 2024; Director for RM Lucas in April 2025. Dr Stenson is the chair of the Risk Committee.

Mr Blackburn has over 25 years of experience in general management, with a record of driving commercial growth. He has been both an entrepreneur and an executive in organisations. He founded Emes, LLC, a technology-based specialty chemical business. Emes had a business model focused on chemical production paired with recycling in the pharmaceutical and consumer healthcare markets. Mr. Blackburn sold the business to Nova Molecular and then joined their executive team to lead further commercial growth of the merged organisations. More recently, Mr. Blackburn was the Vice President of Giant Cement Holdings Inc., and executive manager of its subsidiary, Giant Resource Recovery (GRR), where he led a turn-around of the business resulting in 70% EBITDA growth over two-years. He also raised capital for the GRR business to modernise its plants for profitable growth. He is in daily sales management, marketing and in building a robust supply chain to support sales growth. He is Member of Board of Trustees for International Sleep Products Associations (ISPA) since April 2024 and Member, Sustainability Committee of the Mattress Recycling Council.

Mr Lane has had a career in research, manufacturing, start-ups and product commercialisation including 25 years of senior management positions in the chemical and medical device industries. He has served as CEO/CSO at CAVU group, comprised of Microtek, American Thermal Instruments and Latent Heat Solutions. Mr. Lane has also served on several Boards in the private sector.

Mr Strickland is a member of the Risk Committee. He is an Operating Partner of Colinton Capital Partners. Martyn joined the firm in June 2017 and represents Colinton Capital Partners on AMSG, Alexium and Clear Dynamics investments, where he has recently taken up a role as CEO. Prior to joining Colinton Capital Partners, Martyn was a Senior Partner at Deloitte, where he led their middle-market strategy and the Operational Restructuring and CRO services divisions within the Financial Advisory business. Prior to Deloitte, Martyn joined KordaMentha as Managing Director to establish their 333 Consulting business focusing on company side turnaround, restructuring and growth. Prior to 333, Martyn was Principal with A.T. Kearney and an Operating Executive with Cadbury Schweppes.

Mr Williamson has over 28 years of experience in financial markets and is the Co-Founder and Chief Investment Officer of Wentworth Williamson Management, a shareholder of Alexium International Group Limited. Founded in 2013, Wentworth Williamson Management is a private Australian-based value fund manager with both equity and private credit funds. Prior to Wentworth Williamson, Mr Williamson worked for Allan Gray Australia and prior to that he was Portfolio Manager of the Investec Australian Equity Fund. He is Chairman of Australian Vintage Limited since August 2024.

-

-